Determining optimal timing of birth for women with chronic or gestational hypertension at term: The WILL (When to Induce Labour to Limit risk in pregnancy hypertension) randomised trial. Magee LA, Kirkham K, Tohill S, Gkini E, Moakes CA, Dorling J, Green M, Hutcheon JA, Javed M, Kigozi J, Mol BWM, Singer J, Hardy P, Stubbs C, Thornton JG, von Dadelszen P; WILL Trial Study Group.PLoS Med. 2024 Nov 26;21(11):e1004481. doi: 10.1371/journal.pmed.1004481. eCollection 2024 Nov.PMID: 39591427
Pilot study to evaluate the use of remote patient monitoring to guide the timing of valve intervention in patients with severe asymptomatic aortic stenosis (APRAISE-AS): study protocol for a randomised controlled trial delivered in two tertiary cardiac centres in the UK. Khan N, Steeds RP, Kyte D, Fabritz L, Collis P, Chua W, Stubbs C, Mehta S, Sun Y, Nulty M, Kirkham K, Cotton JM.BMJ Open. 2024 Jun 10;14(6):e086587. doi: 10.1136/bmjopen-2024-086587.
Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM). Perico N, Remuzzi G, Griffin MD, Cockwell P, Maxwell AP, Casiraghi F, Rubis N, Peracchi T, Villa A, Todeschini M, Carrara F, Magee BA, Ruggenenti PL, Rota S, Cappelletti L, McInerney V, Griffin TP, Islam MN, Introna M, Pedrini O, Golay J, Finnerty AA, Smythe J, Fibbe WE, Elliman SJ, O'Brien T; NEPHSTROM Trial Consortium.J Am Soc Nephrol. 2023 Oct 1;34(10):1733-1751. doi: 10.1681/ASN.0000000000000189. Epub 2023 Aug 10.
WILL (When to induce labour to limit risk in pregnancy hypertension): Protocol for a multicentre randomised trial. Kirkham K, Tohill S, Hutcheon JA, Dorling J, Gkini E, Moakes CA, Stubbs C, Thornton J, von Dadelszen P, Magee LA; WILL Trial Study Group.Pregnancy Hypertens. 2023 Jun;32:35-42. doi: 10.1016/j.preghy.2023.03.002. Epub 2023 Apr 3.
WILL (When to Induce Labour to Limit risk in pregnancy hypertension): a multicentre randomised controlled trial - adaptations to deliver a timing-of-birth trial during the COVID-19 international pandemic. Magee LA, Tohill S, Kirkham K, Evans R, Gkini E, Moakes CA, Stubbs C, Thornton J, von Dadelszen P; WILL Trial Study Group.Trials. 2022 Oct 21;23(1):884. doi: 10.1186/s13063-022-06834-4.
Acute Care QUAliTy in chronic Kidney disease (ACQUATIK): a prospective cohort study exploring outcomes of patients with chronic kidney disease. Arnold JJ, Hayer M, Sharif A, Begaj I, Tabriez M, Bagnall D, Ray D, Hoye C, Nazir M, Dutton M, Fifer L, Kirkham K, Sims D, Townend JN, Gill PS, Dasgupta I, Cockwell P, Ferro CJ.BMJ Open. 2015 May 3;5(4):e006987. doi: 10.1136/bmjopen-2014-006987.
E Marston et al Katie Mapp (2009) Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response Blood 113 (1): 117–126. https://doi.org/10.1182/blood-2008-03-142950
R Bruton et al Katie Mapp (2008) Identification of a second CtBP binding site in adenovirus type 5 E1A conserved region 3 Journal of Virology 82(17):8476-86 Identification_of_a_Second_CtBP_Binding_Site_in_Ad.pdf
R Bruton et al Katie Mapp (2007) C-terminal binding protein interacting protein binds directly to adenovirus early region 1A through its N-terminal region and conserved region 3 Oncogene 26, pages 7467–7479 C-terminal-binding protein interacting protein binds directly to adenovirus early region 1A through its N-terminal region and conserved region 3 | Oncogene (nature.com)
D Molloy et al Katie Mapp (2006) Acetylation at a lysine residue adjacent to the CtBP binding motif within adenovirus 12 E1A causes structural disruption and limited reduction of CtBP binding Virology 355(2):115-26 Acetylation at a lysine residue adjacent to the CtBP binding motif within adenovirus 12 E1A causes structural disruption and limited reduction of CtBP binding - PubMed (nih.gov)